Hydrocortisone plus fludrocortisone for community acquired pneumonia-related septic shock: a subgroup analysis of the APROCCHSS phase 3 randomised trial

Background Glucocorticoids probably improve outcomes in patients hospitalised for community acquired pneumonia (CAP) . In this a priori planned exploratory subgroup analysis of the phase 3 randomised controlled Activated Protein C and Corticosteroids for Human Septic Shock (APROCCHSS) trial, we aimed to investigate responses to hydrocortisone plus fludrocortisone between CAP and non -CAP related septic shock. Methods APROCCHSS was a randomised controlled trial that investigated the effects of hydrocortisone plus fludrocortisone, drotrecogin-alfa (activated), or both on mortality in septic shock in a two -by -two factorial design; after drotrecogin-alfa was withdrawn on October 2011, from the market, the trial continued on two parallel groups. It was conducted in 34 centres in France. In this subgroup study, patients with CAP were a preselected subgroup for an exploratory secondary analysis of the APROCCHSS trial of hydrocortisone plus fludrocortisone in septic shock. Adults with septic shock were randomised 1:1 to receive, in a double-blind manner, a 7 -day treatment with daily administration of intravenous hydrocortisone 50 mg bolus every 6h and a tablet of 50 mu g of fludrocortisone via the nasogastric tube, or their placebos. The primary outcome was 90 -day all -cause mortality. Secondary outcomes included all -cause mortality at intensive care unit (ICU) and hospital discharge, 28 -day and 180 -day mortality, the number of days alive and free of vasopressors, mechanical ventilation, or organ failure, and ICU and hospital free -days to 90 -days. Analysis was done in the intention -to -treat population. The trial was registered at ClinicalTrials.gov (NCT00625209). Findings Of 1241 patients included in the APROCCHSS trial, CAP could not be ruled in or out in 31 patients, 562 had a diagnosis of CAP (279 in the placebo group and 283 in the corticosteroid group), and 648 patients did not have CAP (329 in the placebo group and 319 in the corticosteroid group). In patients with CAP, there were 109 (39%) deaths of 283 patients at day 90 with hydrocortisone plus fludrocortisone and 143 (51%) of 279 patients receiving placebo (odds ratio [OR] 0<middle dot>60, 95% CI 0<middle dot>43-0<middle dot>83). In patients without CAP, there were 148 (46%) deaths of 319 patients at day 90 in the hydrocortisone and fludrocortisone group and 157 (48%) of 329 patients in the placebo group (OR 0<middle dot>95, 95% CI 0<middle dot>70-1<middle dot>29). There was significant heterogeneity in corticosteroid effects on 90 -day mortality across subgroups with CAP and without CAP (p=0<middle dot>046 for both multiplicative and additive interaction tests; moderate credibility). Of 1241 patients included in the APROCCHSS trial, 648 (52%) had ARDS (328 in the placebo group and 320 in the corticosteroid group). There were 155 (48%) deaths of 320 patients at day 90 in the corticosteroid group and 186 (57%) of 328 patients in the placebo group. The OR for death at day 90 was 0<middle dot>72 (95% CI 0<middle dot>53-0<middle dot>98) in patients with ARDS and 0<middle dot>85 (0<middle dot>61-1<middle dot>20) in patients without ARDS (p=0<middle dot>45 for multiplicative interaction and p=0<middle dot>42 for additive interaction). The OR for observing at least one serious adverse event (corticosteroid group vs placebo) within 180 days post randomisation was 0<middle dot>64 (95% CI 0<middle dot>46-0<middle dot>89) in the CAP subgroup and 1<middle dot>02 (0<middle dot>75-1<middle dot>39) in the non -CAP subgroup (p=0<middle dot>044 for multiplicative interaction and p=0<middle dot>042 for additive interaction). Interpretation In a pre -specified subgroup analysis of the APROCCHSS trial of patients with CAP and septic shock, hydrocortisone plus fludrocortisone reduced mortality as compared with placebo. Although a large proportion of patients with CAP also met criteria for ARDS, the subgroup analysis was underpowered to fully discriminate between ARDS and CAP modifying effects on mortality reduction with corticosteroids. There was no evidence of a significant treatment effect of corticosteroids in the non -CAP subgroup. Funding Programme Hospitalier de Recherche Clinique of the French Ministry of Health, by Programme d'Investissements d'Avenir, France 2030, and IAHU-ANR-0004. Copyright (c) 2024 Elsevier Ltd. All rights reserved.